Key facts
- It has raised $5.9M; the latest was Seed Round ($5.9M) in Jan 2026.
- Notable investors include IBB Ventures, MSD Global Health Innovation Fund, Catalpa Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Remi (Clinics/Outpatient Services)
- ·The full record, as it builds
Funding rounds
No funding rounds for Remi (Clinics/Outpatient Services) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Remi (Clinics/Outpatient Services)
Provider of at-home diagnostic testing kits intended for accessible sexual health screening. The company's platform includes medically approved collection kits that enable users to privately collect blood and urine samples from home, discreetly send them to certified laboratories abiding by stringent quality and GDPR standards, provide fast and secure digital results accompanied by optional telehealth consultations, enabling individuals and healthcare systems to increase STI detection rates, reduce stigma, enhance early intervention, and streamline patient care pathways.
- Sector
- Healthcare
- HQ
- Potsdam, Germany
- Founded
- 2021
- Employees
- 9
- Website
- myremi.com/
- Ownership
- Privately Held (backing)
Remi (Clinics/Outpatient Services) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Remi (Clinics/Outpatient Services) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Remi (Clinics/Outpatient Services) in its N-PORT filings yet. We sweep new filings monthly.